Final Analysis of PALLAS Shows No Benefit With Palbociclib Plus Endocrine Therapy in Early Breast Cancer
Palbociclib added to adjuvant endocrine therapy failed to improve iDFS.
Andrea S. Blevins Primeau, PhD, MBA
Andrea S. Blevins Primeau, PhD, MBA, is a freelance medical writer and editor based in central Pennsylvania. She enjoys writing about a variety of topics including oncology, cardiovascular disease, and autoimmune disorders. Previously, she conducted research investigating the role of pharmacogenetics on the efficacy of oncologic therapies.
